Contents

Volume 60, Number 1, July 2005

Editors' view

1 Personalized medicine (or drug therapy); the patients' genome, the chip and the physician: *L.D. Lewis*

Editors' report 2004

5 Editors' report 2004: *J.K. Aronson, M.S. Lennard, J.M. Ritter, E.J. Begg & N.S. Baber*

First human use

7 Clinical pharmacology of DP-b99 in healthy volunteers: First administration to humans: *G. Rosenberg, I. Angel & A. Kozak*

Pharmacodynamics

17 Investigation of the effects of physiological and vasodilation-induced autonomic activation on the QTc Interval in healthy male subjects: *E. Berger, K. Patel, S. Anwar, W. Davies & D.J. Sheridan*

24 Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration: *F. Horak, P.U. Zieglmayer, R. Zieglmayer, A. Kavina & P. Lemell*

Pharmacokinetics

32 Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz: *E. Dailly, C. Allavena, F. Raffi & P. Jolliet*

35 Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study: *H. Schmidli, B. Peng, G.-J. Riviere, R. Capdeville, M. Hensley, I. Gathmann, A.E. Bolton & A. Racine-Poon*

45 Dexamethasone as a probe for vinorelbine clearance: *F. Puisset, F. Dalenc, E. Chatelut, T. Cresteil, I. Lochon, P. Tisnes & H. Roché*

Drug metabolism

54 Cytochromes P450 and *MDR1* mRNA expression along the human gastrointestinal tract: *M. Thörn, N. Finnström, S. Lundgren, A. Rane & L. Lööf*

Drug disposition

61 Enantioselective disposition of lansoprazole in relation to *CYP2C19* genotypes in the presence of fluvoxamine: *M. Miura, H. Tada, N. Yasui-Furukori, T. Uno, K. Sugawara, T. Tateishi & T. Suzuki*

69 The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel: *T. Korhonen, A. Tolonen, J. Uusitalo, S. Lundgren, J. Jalonen & K. Laine*

Pharmacoepidemiology

76 Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: Cohort study using data from the UK General Practice Research Database: *S. Russmann, J.A. Kaye, S.S. Jick & H. Jick*

Therapeutics

83 Suboptimal choices and dosing of statins at start of therapy: *A.K. Mantel-Teeuwisse, O.H. Klungel, T. Schalekamp, W.M.M. Verschuren, A.J. Porsius & A. de Boer*

90 Queen Mary Utilization of Antihypertensive Drugs Study: use of antihypertensive drug classes in the Hypertension Clinic 1996–2004: *B.M.Y. Cheung, Y.L. Wong & C.P. Lau*

Short reports

98 Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin®: *H.M. Pearce, D. Layton, L.V. Wilton & S.A.W. Shakir*

103 Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents: *A. Holstein, A. Plaschke, M. Ptak, E.-H. Egberts, J. El-Din, J. Brockmöller & J. Kirchheiner*

107 Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension: *G.A. Paul, J.S.R. Gibbs, A.R. Boobis, A. Abbas & M.R. Wilkins*

Book review

113 Pharmacotherapy of Depression: *edited by D.A. Ciraulo & R.I. Shader; reviewed by E. Szabadi*

114 **Errata**

Letter to the editor

116 Inadvertent intrathecal administration of rifampicin: *N. Senbaga & E.M. Davies*

Contents

Volume 60, Number 1, July 2005

Editors' view

1 Personalized medicine (or drug therapy); the patients' genome, the chip and the physician: *L.D. Lewis*

Editors' report 2004

5 Editors' report 2004: *J.K. Aronson, M.S. Lennard, J.M. Ritter, E.J. Begg & N.S. Baber*

First human use

7 Clinical pharmacology of DP-b99 in healthy volunteers: First administration to humans: *G. Rosenberg, I. Angel & A. Kozak*

Pharmacodynamics

17 Investigation of the effects of physiological and vasodilation-induced autonomic activation on the QTc Interval in healthy male subjects: *E. Berger, K. Patel, S. Anwar, W. Davies & D.J. Sheridan*

24 Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration: *F. Horak, P.U. Zieglmayer, R. Zieglmayer, A. Kavina & P. Lemell*

Pharmacokinetics

32 Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz: *E. Dailly, C. Allavena, F. Raffi & P. Jolliet*

35 Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study: *H. Schmidli, B. Peng, G.-J. Riviere, R. Capdeville, M. Hensley, I. Gathmann, A.E. Bolton & A. Racine-Poon*

45 Dexamethasone as a probe for vinorelbine clearance: *F. Puisset, F. Dalenc, E. Chatelut, T. Cresteil, I. Lochon, P. Tisnes & H. Roché*

Drug metabolism

54 Cytochromes P450 and *MDR1* mRNA expression along the human gastrointestinal tract: *M. Thörn, N. Finnström, S. Lundgren, A. Rane & L. Lööf*

Drug disposition

61 Enantioselective disposition of lansoprazole in relation to *CYP2C19* genotypes in the presence of fluvoxamine: *M. Miura, H. Tada, N. Yasui-Furukori, T. Uno, K. Sugawara, T. Tateishi & T. Suzuki*

69 The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel: *T. Korhonen, A. Tolonen, J. Uusitalo, S. Lundgren, J. Jalonen & K. Laine*

Pharmacoepidemiology

76 Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: Cohort study using data from the UK General Practice Research Database: *S. Russmann, J.A. Kaye, S.S. Jick & H. Jick*

Therapeutics

83 Suboptimal choices and dosing of statins at start of therapy: *A.K. Mantel-Teeuwisse, O.H. Klungel, T. Schalekamp, W.M.M. Verschuren, A.J. Porsius & A. de Boer*

90 Queen Mary Utilization of Antihypertensive Drugs Study: use of antihypertensive drug classes in the Hypertension Clinic 1996–2004: *B.M.Y. Cheung, Y.L. Wong & C.P. Lau*

Short reports

98 Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin®: *H.M. Pearce, D. Layton, L.V. Wilton & S.A.W. Shakir*

103 Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents: *A. Holstein, A. Plaschke, M. Ptak, E.-H. Egberts, J. El-Din, J. Brockmöller & J. Kirchheiner*

107 Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension: *G.A. Paul, J.S.R. Gibbs, A.R. Boobis, A. Abbas & M.R. Wilkins*

Book review

113 Pharmacotherapy of Depression: *edited by D.A. Ciraulo & R.I. Shader; reviewed by E. Szabadi*

114 **Errata**

Letter to the editor

116 Inadvertent intrathecal administration of rifampicin: *N. Senbaga & E.M. Davies*

Volume 60, Number 2, August 2005

Editors' view

117 Metameta-analysis: *J.K. Aronson*

Pharmacodynamics

120 Assessment of the effect of a single oral dose of telithromycin on sotalol-induced QT interval prolongation in healthy women: *J.-L. Démolis, S. Strabach, F. Vacheron & C. Funck-Brentano*

Pharmacokinetics and Pharmacodynamics

128 The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693: *J.P. van der Post, S.J. de Visser, M.L. de Kam, M. Woelfler, D.C. Hilt, J. Vornov, E.S. Burak, E. Bortey, B.S. Slusher, T. Limsakun, A.F. Cohen & J.M.A. van Gerven*

Pharmacoepidemiology

137 Inappropriate drug prescribing in older adults: the updated 2002 Beers criteria – a population-based cohort study: *C.S. van der Hooft, G.W. 't Jong, J.P. Dieleman, K.M.C. Verhamme, T.J.M. van der Cammen, B.H.CH. Stricker, & M.C.J.M. Sturkenboom*

145 Off-label prescribing to children: attitudes and experience of general practitioners: *S. Ekins-Daukes, P.J. Helms, M.W. Taylor & J.S. McLay*

150 Statin use after acute myocardial infarction: a nationwide study in Denmark: *J.N. Rasmussen, G.H. Gislason, S.Z. Abildstrom, S. Rasmussen, I. Gustafsson, P. Buch, J. Friberg, L. Køber, C. Torp-Pedersen, M. Madsen & S. Stender*

Pharmacogenetics

159 Meta-analysis of the influence of *MDR1* C3435T polymorphism on digoxin pharmacokinetics and *MDR1* gene expression: *B. Chowbay, H. Li, M. David, Y.B. Cheung & E.J.D. Lee*

Drug disposition

172 Inhibition of the metabolism of brotizolam by erythromycin in humans: *in vivo* evidence for the involvement of CYP3A4 in brotizolam metabolism: *T. Tokairin, T. Fukasawa, N. Yasui-Furukori, T. Aoshima, A. Suzuki, Y. Inoue, T. Tateishi & K. Otani*

176 Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain: *H. Hiraoka, K. Yamamoto, S. Miyoshi, T. Morita, K. Nakamura, Y. Kadoi, F. Kunimoto & R. Horiuchi*

Therapeutics

183 Pharmaceutical care of patients with heart failure: *A. Sadik, M. Yousif & J.C. McElnay*

Adverse drug effects

194 Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis: *S. Bonovas, K. Filioussi & N.M. Sitaras*

204 Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan: *S. Tsuruoka, M. Wakaumi, T. Ioka, H. Yamamoto, H. Ando, K. Sugimoto & A. Fujimura*

Drug interactions

208 Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide: *M. Niemi, J.T. Backman, L. Juntti-Patinen, M. Neuvonen & P.J. Neuvonen*

Short Reports

218 Profound weight loss associated with reboxetine use in a 44-year-old woman: *T.Y.-T. Lu, A. Kupa, G. Easterbrook & A.A. Mangoni*

221 A distance-learning programme in pharmacovigilance linked to educational credits is associated with improved reporting of suspected adverse drug reactions via the UK yellow card scheme: *R.C.G. Bracchi, J. Houghton, F.J. Woods, S. Thomas, S.A. Smail & P.A. Routledge*

Letter to the Editors

224 Effect of pregnancy on a measure of FMO3 activity: *J. Hukkanen, D. Dempsey, P. Jacob III & N.L. Benowitz*

Book Review

227 Cardiac safety of noncardiac drugs: *edited by Morganroth and Gussack; reviewed by S.H.L. Thomas*

Volume 60, Number 3, September 2005

Editors' view

229 Monitoring therapy: *J.K. Aronson*

Editorial commentary

231 Changes in the usage of antihypertensive drugs: implications and prospects: *M. Schachter*

Review

235 The functional significance of genetic variation within the β_1-adrenoceptor: *A.J. Sandilands & K.M. O'Shaughnessy*

Pharmacokinetics & Pharmacodynamics

244 Pharmacokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test: *D.J. Greenblatt, L. Gan, J.S. Harmatz & R.I. Shader*

Pharmacokinetics

249 Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling: *S. Cremers, R. Schoemaker, E. Scholten, J. den Hartigh, J. König-Quartel, E. van Kan, L. Paul & J. de Fijter*

257 Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis: *V. Chan, B.G. Charles & S.E. Tett*

265 Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation: *H. Mulla1 & S. Pooboni*

276 Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients: *B.S. Kappelhoff, A.D.R. Huitema, S.U.C. Sankatsing, P.L. Meenhorst, E.C.M. Van Gorp, J.W. Mulder, J.M. Prins & J.H. Beijnen*

Drug interactions

287 The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects: *D. Malling, M.N. Poulsen & B. Søgaard*

Therapeutic drug monitoring

291 Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic: *J.E. Ray, D. Marriott, M.T. Bloch & A.J. McLachlan*

Therapeutics

300 Antihypertensive drug prescribing in Grampian: *S. Ross & M.J. Macleod*

306 Concomitant use of analgesics and psychotropics in home-dwelling elderly people – Kuopio 75 + study: *S. Hartikainen, P. Mäntyselkä, K. Louhivuori-Laako, H. Enlund & R. Sulkava*

311 Oral opioid administration and hyperalgesia in patients with cancer or chronic nonmalignant pain: *I. Reznikov, D. Pud & E. Eisenberg*

319 Leflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation: *E.N. van Roon, M. Hoekstra, H. Tobi, T.L.T.A. Jansen, H.J.B. Moens, J.R.B.J. Brouwers & M.A.F.J. van de Laar*

Short reports

326 Potential for drug interactions involving cytochrome P450 in patients attending palliative day care centres: a multicentre audit: *A. Wilcock, J. Thomas, J. Frisby, M. Webster, V. Keeley, G. Finn, K. Fossey, B. Wee, J. Beale & M.S. Lennard*

330 Ziprasidone decreases cortisol excretion in healthy subjects: *A. Meier, A.-C. Neumann, W. Jordan, G. Huether, A. Rodenbeck, E. Rüther & S. Cohrs*

337 Effects of grapefruit juice on the absorption of levothyroxine: *J.J. Lilja, K. Laitinen & P.J. Neuvonen*

Letter to the Editors

342 An unexpected response to intravenous hydrocortisone succinate in an asthmatic patient: *G.P. Currie, E. Paterson, F. Keenan, S. Nath & S.J. Watt*

343 **Erratum**

Volume 60, Number 4, October 2005

Editors' view

345 One hundred years of atrial fibrillation: *J.K. Aronson*

Systematic review

347 Rhythm *vs.* rate control of atrial fibrillation meta-analysed by number needed to treat: *C.R. Kumana, B.M.Y. Cheung, G.T.Y. Cheung, T. Ovedal, B. Pederson & I.J. Lauder*

Pharmacodynamics

355 Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance: *A.S. Holmes, Y.Y. Chirkov, S.R. Willoughby, S. Poropat, J. Pereira & J.D. Horowitz*

364 Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis: *P. Sanchez-Pena, J.-S. Hulot, S. Urien, A. Ankri, J.-P. Collet, R. Choussat, P. Lechat & G. Montalescot*

Pharmacokinetics

374 Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for *Helicobacter pylori* eradication: *J. Spénard, C. Aumais, J. Massicotte, J.-S. Brunet, C. Tremblay, M. Grace & M. Lefebvre*

378 Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients: *K.M.L. Crommentuyn, B.S. Kappelhoff, J.W. Mulder, A.T.A. Mairuhu, E.C.M. van Gorp, P.L. Meenhorst, A.D.R. Huitema & J.H. Beijnen*

390 Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected

patients on HAART: *X. Panhard, C. Goujard, M. Legrand, A. M. Taburet, B. Diquet, F. Mentré and the COPHAR 1-ANRS study group*

Pharmacodynamics & pharmacokinetics

404 Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects: *J. Hanna, D.J.R. Foster, A. Salter, A.A. Somogyi, J.M. White & F. Bochner*

Pharmacogenetics

414 No positive association between adrenergic receptor variants of α_{2c}Del322–325, β_1Ser49, β_1Arg389 and the risk for heart failure in the Japanese population: *S. Nonen, H. Okamoto, M. Akino, Y. Matsui, Y. Fujio, M. Yoshiyama, Y. Takemoto, J. Yoshikawa, J. Azuma & A. Kitabatake*

418 Allele and genotype frequencies of *CYP2C9* in a Korean population: *J.-W. Bae, H.-K. Kim, J.-H. Kim, S.-I. Yang, M.-J. Kim, C.-G. Jang, Y.-S. Park & S.-Y. Lee*

Drug disposition

423 S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen: *K. Bowalgaha, D.J. Elliot, P.I. Mackenzie, K.M. Knights, S. Swedmark & J.O. Miners*

Drug interaction

434 Pharmacokinetic interaction between verapamil and everolimus in healthy subjects: *J. M. Kovarik, D. Beyer, M.N. Bizot, Q. Jiang, M.J. Allison & R.L. Schmouder*

Therapeutics

438 Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs: *M.C.J.M. Sturkenboom, W.G. Goettsch, G. Picelli, Bas in 't Veld, D.D. Yin, R.B. de Jong, P.M.N.Y.H. Go & R.M.C. Herings*

Clinical toxicology

444 Co-proxamol overdose is associated with a 10-fold excess mortality compared with other paracetamol combination analgesics: *R. Afshari, A.M. Good, S.R.J. Maxwell & D.N. Bateman*

Short report

448 The quality of information on monitoring for haematological adverse drug reactions: *R.E. Ferner, J. Coleman, M. Pirmohamed, S.A. Constable & A. Rouse*

Letter to the editors

452 Estimation of time devoted to adverse drug reactions assessment in an internal medicine department: *N. Tavassoli, H. Bagheri, L. Sailler, P. Benkemoun, J.-L. Montastruc & P. Arlet*

Book review

454 Side-effects of Drugs Annual 27: *edited by J.K. Aronson; reviewed by R.E. Ferner*

455 **Erratum**

Volume 60, Number 5, November 2005

Editors' view

457 Prescribing statins: *J.K. Aronson*

Pharmacodynamics

459 The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease: *D. Patterson, R. Kloner, M. Effron, J. Emmick, A. Bedding, M. Warner, M. Mitchell, S. Braat & T. MacDonald*

Pharmacokinetics

469 Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment: *G. Holmes, L. Galitz, P. Hu & W. Lyness*

477 Population plasma pharmacokinetics of ^{11}C-flumazenil at tracer concentrations: *C.M. van Rij, A.D.R. Huitema, E.L. Swart, H.N.J.M. Greuter, A.A. Lammertsma, A.C. van Loenen & E.J.F. Franssen*

Pharmacokinetics-Pharmacodynamics

486 Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics: *K.E. Culm-Merdek, L.L. von Moltke, J.S. Harmatz & D.J. Greenblatt*

Interactions

494 Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin: *H. Ando, S. Tsuruoka, H. Yanagihara, K.-I. Sugimoto, M. Miyata, Y. Yamazoe, T. Takamura, S. Kaneko & A. Fujimura*

498 Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide: *A.S. Jakate, P. Roy, A. Patel, W. Abramowitz, S. Persiani, J. Wangsa & R. Kapil*

508 Prediction of *in vivo* drug–drug interactions from *in vitro* data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant: *H.S. Brown, K. Ito, A. Galetin & J.B. Houston*

Pharmacoepidemiology

519 Suicide and self-harm following prescription of SSRIs and other antidepressants: confounding by indication: *R.C. Didham, D.W. McConnell, H.J. Blair & D.M. Reith*

Therapeutics

526 General practitioners' adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study: *T. Dybdahl, M. Andersen, J. Kragstrup, I.S. Kristiansen & J. Søndergaard*

534 Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study: *R.W. Thomsen, S.P. Johnsen, A.V. Olesen, J.T. Mortensen, H. Bøggild, J. Olsen & H.T. Sørensen*

543 Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003: *T. Walley, P. Folino-Gallo, P. Stephens & E. Van Ganse on behalf of the EuroMedStat group*

Adverse drug effects

552 Calcium antagonists and deep gingival pockets in the population-based SHIP study: *P. Meisel, C. Schwahn, U. John, H.K. Kroemer & T. Kocher*

Short reports

560 Relationships between sirolimus dosing, concentration and outcomes in renal transplant recipients: *C. Dansirikul, S.B. Duffull, R.G. Morris1 & S.E. Tett*

566 Trimethoprim–sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients: *Y. Böttiger, C. Brattström, L. Bäckman, K. Claesson & J.T. Burke*

570 Mirtazapine-induced arthralgia: *A. Passier & E. van Puijenbroek*

573 Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation: *M. Brunner, P. Dehghanyar, B. Seigfried, W. Martin, G. Menke & M. Müller*

Letter to the editor

578 Topiramate in non-approved indications and acute myopia or angle closure glancoma: *G. Cereza, C. Pedrós, N. Garcia & J.-R. Laporte*

Volume 60, Number 6, December 2005

Editors' view

581 Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed: *L. Aarons*

Pharmacokinetics and Pharmacodynamics

584 Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using ^{13}C-uracil as an *in vivo* probe: *S. Ito, T. Kawamura, M. Inada, Y. Inoue, Y. Hirao, T. Koga, J.-I. Kunizaki, T. Shimizu & H. Sato*

594 Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin: *T. Gordi, R. Xie & W.J. Jusko*

605 Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge: *H.S. Tomlinson, S.A. Corlett, M.B. Allen & H. Chrystyn*

611 Vasodilator effects of the endothelin ET_A receptor selective antagonist BMS-193884 in healthy men: *N. Dhaun, F.E. Strachan, D.E. Newby, N.R. Johnston, N.F. Ford, J.L. Hammett, M. Palmisano & D.J. Webb*

Pharmacogenetics

623 Polymorphisms in genes encoding acetylsalicylic acid metabolizing enzymes are unrelated to upper gastrointestinal health in cardiovascular patients on acetylsalicylic acid: *M.G.H. van Oijen, S. Huybers, W.H.M. Peters, J.P.H. Drenth, R.J.F. Laheij, F.W.A. Verheugt & J.B.M.J. Jansen*

629 Gender specific association of *CYP2C9*3* with hyperlipidaemia in Chinese: *C.-H. Luo, A. Wang, R.-H. Zhu, W.-X. Zhang, W. Mo, B.-N. Yu, G.L. Chen, D.-S. Ou-Yang, X.-H. Duan, A.M.A. El-Aty & H.-H. Zhou*

Drug Disposition

632 Sulphation of o-desmethylnaproxen and related compounds by human cytosolic sulfotransferases: *C.N. Falany, P. Ström & S. Swedmark*

Pharmacoepidemiology

641 Dramatic change in prescribing of hormone replacement therapy in the Netherlands after publication of the Million Women Study: a follow-up study: *A. Faber, M.L. Bouvy, L. Loskamp, P.B. van de Berg, T.C.G. Egberts & L.T.W. de Jong-van den Berg*

Therapeutics

648 Usage of paracetamol-containing combination analgesics remains high in primary care: *C. Usher, M. Teeling, K. Bennett, B. McGowan & J. Feely*

Adverse drug effects

653 Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital: *A. Vallano, G. Cereza, C. Pedròs, A. Agustí, I. Danés, C. Aguilera & J.M. Arnau*

Short report

659 Effects of grapefruit juice on the pharmacokinetics of acebutolol: *J.J. Lilja, K. Raaska & P.J. Neuvonen*

Letters to the editors

664 Nasal septal perforation enlargement related to topical ocular steroids: *M.Y. Chiang & P. Shah*

666 Interstitial pneumonitis during lamotrigine therapy: *N. Saravanan, O.M. Otaiku & R.N. Namushi*

668 Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial: *D.Y.L. Leung, Y.Y.Y. Kwong & D.S.C. Lam*

669 Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial: *R. Altan-Yaycioglu, O. Yaycioglu & Y.A. Akova*

670 Proceedings of the Dutch Society of Clinical Pharmacology and Biopharmacy meeting of April 13th 2005

684 Indices for Volume 60

692 Reviewers for 2005